News

Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...
Vertex to stop developing new painkiller as solo treatment after mid-stage study setback
Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo ...
Vertex next-generation pain candidate fails Phase 2 trial
The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint -- ...
Vertex: Q2 Earnings Snapshot
BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported second-quarter profit of $1.03 billion. The Boston-based company said it had net income of $3.99 per share. Earnings, ...
Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb
Vertex Pharmaceuticals swung to a profit and logged higher sales in the second quarter, as more people used its cystic-fibrosis drug and the biotechnology company began rolling out new therapies.
Vertex Reports Second Quarter 2025 Financial Results
-- Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion -- ...